Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease

Brain Imaging and Behavior

Volumn 6, Issue 4, 2012, Pages 568-583

  Habeck, Christian ^a   Risacher, Shannon ^b   Lee, Grace J ^c   Glymour, M Maria ^d   Mormino, Elizabeth ^e   Mukherjee, Shubhabrata ^f   Kim, Sungeun ^b   Nho, Kwangsik ^b   DeCarli, Charles ^g   Saykin, Andrew J ^b   Crane, Paul K ^f  

^a Howard Hughes Medical Institute   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease (AD); Executive function; FDG PET; Memory; Mild cognitive impairment (MCI)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; BRAIN REGION; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; ORBITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE;

EID: 84871722016     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-012-9208-x     Document Type: Article

References (83)

1. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., & Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7(3), 270-279. doi: 10. 1016/j. jalz. 2011. 03. 008.
2. Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002). Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. The American Journal of Psychiatry, 159(5), 738-745.
3. Baudic, S., Barba, G. D., Thibaudet, M. C., Smagghe, A., Remy, P., & Traykov, L. (2006). Executive function deficits in early Alzheimer's disease and their relations with episodic memory. Archives of Clinical Neuropsychology, 21(1), 15-21. doi: 10. 1016/j. acn. 2005. 07. 002.
4. Bohnen, N. I., Djang, D. S., Herholz, K., Anzai, Y., & Minoshima, S. (2012). Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: A review of the recent literature. Journal of Nuclear Medicine, 53(1), 59-71. doi: 10. 2967/jnumed. 111. 096578.
5. Bracco, L., Bessi, V., Piccini, C., Mosconi, L., Pupi, A., & Sorbi, S. (2007). Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease. Journal of Neurology, 254(8), 1052-1065. doi: 10. 1007/s00415-006-0488-1.
6. Brickman, A. M., Siedlecki, K. L., Muraskin, J., Manly, J. J., Luchsinger, J. A., Yeung, L. K., & Stern, Y. (2011). White matter hyperintensities and cognition: Testing the reserve hypothesis. Neurobiology of Aging, 32(9), 1588-1598. doi: 10. 1016/j. neurobiolaging. 2009. 10. 013.
7. Carmichael, O., Schwarz, C., Drucker, D., Fletcher, E., Harvey, D., Beckett, L., & DeCarli, C. (2010). Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Archives of Neurology, 67(11), 1370-1378. doi: 10. 1001/archneurol. 2010. 284.
8. Chen, K., Ayutyanont, N., Langbaum, J. B., Fleisher, A. S., Reschke, C., Lee, W., & Reiman, E. M. (2011). Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage, 56(1), 52-60. doi: 10. 1016/j. neuroimage. 2011. 01. 049.
9. Chen, K., Langbaum, J. B., Fleisher, A. S., Ayutyanont, N., Reschke, C., Lee, W., & Reiman, E. M. (2010). Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage, 51(2), 654-664. doi: 10. 1016/j. neuroimage. 2010. 02. 064.
10. Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Berkouk, K., Landeau, B., & Eustache, F. (2003). Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain, 126(Pt 9), 1955-1967. doi: 10. 1093/brain/awg196.
11. Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Eustache, F., & Baron, J. C. (2003). Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology, 60(8), 1374-1377.
12. Chow, T. W., Graff-Guerrero, A., Verhoeff, N. P., Binns, M. A., Tang-Wai, D. F., Freedman, M., & Pollock, B. G. (2011). Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatric Disease and Treatment, 7, 415-424. doi: 10. 2147/NDT. S22635.
13. Collette, F., Salmon, E., van der Linden, M., Degueldre, C., & Franck, G. (1997). Functional anatomy of verbal and visuospatial span tasks in Alzheimer's disease. [Clinical Trial Controlled Clinical Trial Research Support, Non-U. S. Gov't]. Human Brain Mapping, 5(2), 110-118.
14. Collette, F., van der Linden, M., Delrue, G., & Salmon, E. (2002). Frontal hypometabolism does not explain inhibitory dysfunction in Alzheimer disease. [Research Support, Non-U. S. Gov't]. Alzheimer Disease and Associated Disorders, 16(4), 228-238.
15. Crane, P. K., Carle, A., Gibbons, L. E., Insel, P., Mackin, R. S., Gross, A., . . . for the Alzheiemer's Disease Neuroimaging Initiative. (2011). Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior.
16. de Leon, M. J., Mosconi, L., Blennow, K., DeSanti, S., Zinkowski, R., Mehta, P. D., & Rusinek, H. (2007). Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Annals of the New York Academy of Sciences, 1097, 114-145. doi: 10. 1196/annals. 1379. 012.
17. Del Sole, A., Clerici, F., Chiti, A., Lecchi, M., Mariani, C., Maggiore, L., & Lucignani, G. (2008). Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: An FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 35(7), 1357-1366. doi: 10. 1007/s00259-008-0773-6.
18. Desgranges, B., Baron, J. C., de la Sayette, V., Petit-Taboue, M. C., Benali, K., Landeau, B., & Eustache, F. (1998). The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain, 121(Pt 4), 611-631.
19. Desgranges, B., Baron, J. C., Lalevee, C., Giffard, B., Viader, F., de La Sayette, V., & Eustache, F. (2002). The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: Relationship to degree of deterioration. Brain, 125(Pt 5), 1116-1124.
20. Drzezga, A., Grimmer, T., Riemenschneider, M., Lautenschlager, N., Siebner, H., Alexopoulus, P., & Kurz, A. (2005). Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. Journal of Nuclear Medicine, 46(10), 1625-1632.
21. Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., & Brooks, D. J. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology, 68(7), 501-508. doi: 10. 1212/01. wnl. 0000244749. 20056. d4.
22. Eustache, F., Desgranges, B., Giffard, B., de la Sayette, V., & Baron, J. C. (2001). Entorhinal cortex disruption causes memory deficit in early Alzheimer's disease as shown by PET. Neuroreport, 12(4), 683-685.
23. Gibbons, L. E., Carle, A. C., Mackin, R. S., Harvey, D., Mukherjee, S., Insel, P., . . . for the Alzheiemer's Disease Neuroimaging Initiative. (2011). A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior.
24. Habeck, C., Foster, N. L., Perneczky, R., Kurz, A., Alexopoulos, P., Koeppe, R. A., & Stern, Y. (2008). Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. NeuroImage, 40(4), 1503-1515. doi: 10. 1016/j. neuroimage. 2008. 01. 056.
25. Haense, C., Herholz, K., Jagust, W. J., & Heiss, W. D. (2009). Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dementia and Geriatric Cognitive Disorders, 28(3), 259-266. doi: 10. 1159/000241879.
26. Herholz, K. (1995). FDG PET and differential diagnosis of dementia. Alzheimer Disease and Associated Disorders, 9(1), 6-16.
27. Herholz, K. (2003). PET studies in dementia. Annals of Nuclear Medicine, 17(2), 79-89.
28. Herholz, K., Salmon, E., Perani, D., Baron, J. C., Holthoff, V., Frolich, L., & Heiss, W. D. (2002). Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage, 17(1), 302-316.
29. Herholz, K., Westwood, S., Haense, C., & Dunn, G. (2011). Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine, 52(8), 1218-1226. doi: 10. 2967/jnumed. 111. 090902.
30. Jagust, W., Reed, B., Mungas, D., Ellis, W., & Decarli, C. (2007). What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology, 69(9), 871-877. doi: 10. 1212/01. wnl. 0000269790. 05105. 16.
31. Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., & Koeppe, R. A. (2010). The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's & Dementia, 6(3), 221-229. doi: 10. 1016/j. jalz. 2010. 03. 003.
32. Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., & Mathis, C. A. (2009). Relationships between biomarkers in aging and dementia. [Comparative Study Multicenter Study Research Support, N. I. H., Extramural Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, Non-P. H. S.]. Neurology, 73(15), 1193-1199. doi: 10. 1212/WNL. 0b013e3181bc010c.
33. Kalpouzos, G., Eustache, F., de la Sayette, V., Viader, F., Chetelat, G., & Desgranges, B. (2005). Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients. Journal of Neurology, 252(5), 548-558. doi: 10. 1007/s00415-005-0685-3.
34. Kanda, T., Ishii, K., Uemura, T., Miyamoto, N., Yoshikawa, T., Kono, A. K., & Mori, E. (2008). Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. European Journal of Nuclear Medicine and Molecular Imaging, 35(12), 2227-2234. doi: 10. 1007/s00259-008-0871-5.
35. Karow, D. S., McEvoy, L. K., Fennema-Notestine, C., Hagler, D. J., Jr., Jennings, R. G., Brewer, J. B., & Dale, A. M. (2010). Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology, 256(3), 932-942. doi: 10. 1148/radiol. 10091402.
36. Kessler, J., Mielke, R., Grond, M., Herholz, K., & Heiss, W. D. (2000). Frontal lobe tasks do not reflect frontal lobe function in patients with probable Alzheimer's disease. International Journal of Neuroscience, 104(1-4), 1-15.
37. Kim, S. H., Seo, S. W., Yoon, D. S., Chin, J., Lee, B. H., Cheong, H. K., & Na, D. L. (2010). Comparison of neuropsychological and FDG-PET findings between early-versus late-onset mild cognitive impairment: A five-year longitudinal study. Dementia and Geriatric Cognitive Disorders, 29(3), 213-223. doi: 10. 1159/000278422.
38. Kono, A. K., Ishii, K., Sofue, K., Miyamoto, N., Sakamoto, S., & Mori, E. (2007). Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. European Journal of Nuclear Medicine and Molecular Imaging, 34(9), 1490-1497. doi: 10. 1007/s00259-007-0380-y.
39. Lancaster, J. L., Rainey, L. H., Summerlin, J. L., Freitas, C. S., Fox, P. T., Evans, A. C., & Mazziotta, J. C. (1997). Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward-transform method. Human Brain Mapping, 5(4), 238-242. doi: 10. 1002/(SICI)1097-0193(1997)5: 4< 238:: AID-HBM6> 3. 0. CO; 2-4.
40. Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., & Jagust, W. J. (2011). Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging, 32(7), 1207-1218. doi: 10. 1016/j. neurobiolaging. 2009. 07. 002.
41. Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., & Jagust, W. J. (2010). Comparing predictors of conversion and decline in mild cognitive impairment. [Comparative Study Research Support, N. I. H., Extramural Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, Non-P. H. S.]. Neurology, 75(3), 230-238. doi: 10. 1212/WNL. 0b013e3181e8e8b8.
42. Langbaum, J. B., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., & Reiman, E. M. (2009). Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage, 45(4), 1107-1116. doi: 10. 1016/j. neuroimage. 2008. 12. 072.
43. Lee, D. Y., Seo, E. H., Choo, I. H., Kim, S. G., Lee, J. S., Lee, D. S., & Woo, J. I. (2008). Neural correlates of the clock drawing test performance in Alzheimer's disease: A FDG-PET study. Dementia and Geriatric Cognitive Disorders, 26(4), 306-313. doi: 10. 1159/000161055.
44. Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., & de Leon, M. J. (2008). Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 35(12), 2169-2181. doi: 10. 1007/s00259-008-0833-y.
45. Lo, R. Y., Hubbard, A. E., Shaw, L. M., Trojanowski, J. Q., Petersen, R. C., Aisen, P. S., & Jagust, W. J. (2011). Longitudinal change of biomarkers in cognitive decline. Archives of Neurology, 68(10), 1257-1266. doi: 10. 1001/archneurol. 2011. 123.
46. Lowe, V. J., Kemp, B. J., Jack, C. R., Jr., Senjem, M., Weigand, S., Shiung, M., & Petersen, R. C. (2009). Comparison of 18F-FDG and PiB PET in cognitive impairment. Journal of Nuclear Medicine, 50(6), 878-886. doi: 10. 2967/jnumed. 108. 058529.
47. Lucignani, G., & Nobili, F. (2010). FDG-PET for early assessment of Alzheimer's disease: Isn't the evidence base large enough? European Journal of Nuclear Medicine and Molecular Imaging, 37(8), 1604-1609. doi: 10. 1007/s00259-010-1535-9.
48. Messa, C., Perani, D., Lucignani, G., Zenorini, A., Zito, F., Rizzo, G., et al. (1994). High-resolution technetium-99 m-HMPAO SPECT in patients with probable Alzheimer's disease: Comparison with fluorine-18-FDG PET. Journal of Nuclear Medicine, 35(2), 210-216.
49. Mielke, R., Pietrzyk, U., Jacobs, A., Fink, G. R., Ichimiya, A., Kessler, J., & Heiss, W. D. (1994). HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: Comparison of perfusion and metabolic pattern. European Journal of Nuclear Medicine, 21(10), 1052-1060.
50. Minoshima, S., Frey, K. A., Koeppe, R. A., Foster, N. L., & Kuhl, D. E. (1995). A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine, 36(7), 1238-1248.
51. Morinaga, A., Ono, K., Ikeda, T., Ikeda, Y., Shima, K., Noguchi-Shinohara, M., & Yamada, M. (2010). A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dementia and Geriatric Cognitive Disorders, 30(4), 285-292. doi: 10. 1159/000320265.
52. Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., & Jagust, W. J. (2009). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. [Comparative Study Research Support, N. I. H., Extramural]. Brain, 132(5), 1310-1323. doi: 10. 1093/brain/awn320.
53. Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. European Journal of Nuclear Medicine and Molecular Imaging, 32(4), 486-510. doi: 10. 1007/s00259-005-1762-7.
54. Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., & de Leon, M. J. (2010). Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. Journal of Alzheimer's Disease, 20(3), 843-854. doi: 10. 3233/JAD-2010-091504.
55. Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., & Pupi, A. (2004). MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology, 63(12), 2332-2340.
56. Mosconi, L., Tsui, W. H., De Santi, S., Li, J., Rusinek, H., Convit, A., & de Leon, M. J. (2005). Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis. Neurology, 64(11), 1860-1867. doi: 10. 1212/01. WNL. 0000163856. 13524. 08.
57. Mosconi, L., Tsui, W. H., Pupi, A., De Santi, S., Drzezga, A., Minoshima, S., & de Leon, M. J. (2007). (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. Journal of Nuclear Medicine, 48(7), 1129-1134. doi: 10. 2967/jnumed. 107. 040675.
58. Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., & Beckett, L. (2005a). The Alzheimer's disease neuroimaging initiative. Neuroimaging Clinics of North America, 15(4), 869-877. doi: 10. 1016/j. nic. 2005. 09. 008. xi-xii.
59. Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., & Beckett, L. (2005b). Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia, 1(1), 55-66. doi: 10. 1016/j. jalz. 2005. 06. 003.
60. Nestor, P. G., Parasuraman, R., Haxby, J. V., & Grady, C. L. (1991). Divided attention and metabolic brain dysfunction in mild dementia of the Alzheimer's type. [Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, P. H. S.]. Neuropsychologia, 29(5), 379-387.
61. Nishi, H., Sawamoto, N., Namiki, C., Yoshida, H., Dinh, H. D., Ishizu, K., & Fukuyama, H. (2010). Correlation between cognitive deficits and glucose hypometabolism in mild cognitive impairment. [Research Support, Non-U. S. Gov't]. Journal of Neuroimaging, 20(1), 29-36. doi: 10. 1111/j. 1552-6569. 2008. 00328. x.
62. Nobili, F., Salmaso, D., Morbelli, S., Girtler, N., Piccardo, A., Brugnolo, A., & Pagani, M. (2008). Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging, 35(12), 2191-2202. doi: 10. 1007/s00259-008-0869-z.
63. Noble, J. M., & Scarmeas, N. (2009). Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment. International Review of Neurobiology, 84, 133-149. doi: 10. 1016/S0074-7742(09)00407-3.
64. Perani, D., Bressi, S., Cappa, S. F., Vallar, G., Alberoni, M., Grassi, F., et al. (1993). Evidence of multiple memory systems in the human brain. A [18F]FDG PET metabolic study. Brain, 116(4), 903-919.
65. Petersen, R. C. (2000). Mild cognitive impairment: Transition between aging and Alzheimer's disease. Neurologia, 15(3), 93-101.
66. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56(3), 303-308.
67. Piert, M., Koeppe, R. A., Giordani, B., Berent, S., & Kuhl, D. E. (1996). Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. Journal of Nuclear Medicine, 37(2), 201-208.
68. Poljansky, S., Ibach, B., Hirschberger, B., Manner, P., Klunemann, H., Hajak, G., & Marienhagen, J. (2011). A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. European Archives of Psychiatry and Clinical Neuroscience, 261(6), 433-446. doi: 10. 1007/s00406-010-0184-0.
69. Pontecorvo, M. J., & Mintun, M. A. (2011). PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther, 3(2), 11. doi: 10. 1186/alzrt70.
70. Reiman, E. M. (2011). Fluorodeoxyglucose positron emission tomography: Emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiology of Aging, 32(Suppl 1), S44-47. doi: 10. 1016/j. neurobiolaging. 2011. 09. 007.
71. Rimajova, M., Lenzo, N. P., Wu, J. S., Bates, K. A., Campbell, A., Dhaliwal, S. S., & Martins, R. N. (2008). Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. Journal of Alzheimer's Disease, 13(2), 137-146.
72. Samuraki, M., Matsunari, I., Chen, W. P., Yajima, K., Yanase, D., Fujikawa, A., & Yamada, M. (2007). Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 34(10), 1658-1669. doi: 10. 1007/s00259-007-0454-x.
73. Schonknecht, O. D., Hunt, A., Toro, P., Guenther, T., Henze, M., Haberkorn, U., & Schroder, J. (2011). Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease. Clinical EEG and Neuroscience, 42(2), 71-76.
74. Schonknecht, O. D., Hunt, A., Toro, P., Henze, M., Haberkorn, U., & Schroder, J. (2009). Neural correlates of delayed episodic memory in patients with mild cognitive impairment--a FDG PET study. [Research Support, Non-U. S. Gov't]. Neuroscience Letters, 467(2), 100-104. doi: 10. 1016/j. neulet. 2009. 10. 014.
75. Silverman, D. H., Small, G. W., Chang, C. Y., Lu, C. S., Kung De Aburto, M. A., Chen, W., & Phelps, M. E. (2001). Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. Journal of the American Medical Association, 286(17), 2120-2127.
76. Slansky, I., Herholz, K., Pietrzyk, U., Kessler, J., Grond, M., Mielke, R., & Heiss, W. D. (1995). Cognitive impairment in Alzheimer's disease correlates with ventricular width and atrophy-corrected cortical glucose metabolism. Neuroradiology, 37(4), 270-277.
77. Stopford, C. L., Thompson, J. C., Neary, D., Richardson, A. M., & Snowden, J. S. (2010). Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia. Cortex. doi: 10. 1016/j. cortex. 2010. 12. 002.
78. Teipel, S. J., Willoch, F., Ishii, K., Burger, K., Drzezga, A., Engel, R., & Hampel, H. (2006). Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiology of Aging, 27(5), 681-690. doi: 10. 1016/j. neurobiolaging. 2005. 03. 015.
79. von Borczyskowski, D., Wilke, F., Martin, B., Brenner, W., Clausen, M., Mester, J., & Buchert, R. (2006). Evaluation of a new expert system for fully automated detection of the Alzheimer's dementia pattern in FDG PET. Nuclear Medicine Communications, 27(9), 739-743. doi: 10. 1097/01. mnm. 0000230078. 25609. 2b.
80. Walhovd, K. B., Fjell, A. M., Brewer, J., McEvoy, L. K., Fennema-Notestine, C., Hagler, D. J., Jr., & Dale, A. M. (2010). Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR. American Journal of Neuroradiology, 31(2), 347-354. doi: 10. 3174/ajnr. A1809.
81. Walhovd, K. B., Fjell, A. M., Dale, A. M., McEvoy, L. K., Brewer, J., Karow, D. S., & Fennema-Notestine, C. (2010). Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiology of Aging, 31(7), 1107-1121. doi: 10. 1016/j. neurobiolaging. 2008. 08. 013.
82. Weiner, M. W., Aisen, P. S., Jack, C. R., Jr., Jagust, W. J., Trojanowski, J. Q., Shaw, L., & Schmidt, M. (2010). The Alzheimer's disease neuroimaging initiative: Progress report and future plans. Alzheimer's & Dementia, 6(3), 202-211. e207.
83. Yun, J. Y., Lee, D. Y., Seo, E. H., Choo, I. H., Park, S. Y., Kim, S. G., & Woo, J. I. (2011). Neural Correlates of Stroop Performance in Alzheimer's Disease: A FDG-PET Study. Dement Geriatr Cogn Dis Extra, 1(1), 190-201. doi: 10. 1159/000329517.